Erasca (ERAS) Competitors $2.38 +0.17 (+7.69%) Closing price 04:00 PM EasternExtended Trading$2.32 -0.06 (-2.48%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ERAS vs. SRRK, NTLA, HCM, ALVO, BEAM, CDTX, IDYA, RXRX, APGE, and CPRXShould you be buying Erasca stock or one of its competitors? The main competitors of Erasca include Scholar Rock (SRRK), Intellia Therapeutics (NTLA), HUTCHMED (HCM), Alvotech (ALVO), Beam Therapeutics (BEAM), Cidara Therapeutics (CDTX), IDEAYA Biosciences (IDYA), Recursion Pharmaceuticals (RXRX), Apogee Therapeutics (APGE), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry. Erasca vs. Its Competitors Scholar Rock Intellia Therapeutics HUTCHMED Alvotech Beam Therapeutics Cidara Therapeutics IDEAYA Biosciences Recursion Pharmaceuticals Apogee Therapeutics Catalyst Pharmaceuticals Erasca (NASDAQ:ERAS) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings. Is ERAS or SRRK more profitable? Erasca's return on equity of -31.19% beat Scholar Rock's return on equity.Company Net Margins Return on Equity Return on Assets ErascaN/A -31.19% -26.34% Scholar Rock N/A -127.11%-90.09% Do insiders & institutionals hold more shares of ERAS or SRRK? 67.8% of Erasca shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 14.4% of Erasca shares are held by insiders. Comparatively, 13.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, ERAS or SRRK? Erasca has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Do analysts rate ERAS or SRRK? Erasca currently has a consensus price target of $3.75, indicating a potential upside of 57.56%. Scholar Rock has a consensus price target of $48.50, indicating a potential upside of 63.41%. Given Scholar Rock's stronger consensus rating and higher possible upside, analysts plainly believe Scholar Rock is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Erasca 2 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.44Scholar Rock 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 3 Strong Buy rating(s) 3.07 Which has better earnings and valuation, ERAS or SRRK? Erasca has higher earnings, but lower revenue than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErascaN/AN/A-$161.65M-$0.45-5.29Scholar Rock$33.19M85.96-$246.29M-$2.91-10.20 Does the media prefer ERAS or SRRK? In the previous week, Scholar Rock had 6 more articles in the media than Erasca. MarketBeat recorded 8 mentions for Scholar Rock and 2 mentions for Erasca. Erasca's average media sentiment score of 0.34 beat Scholar Rock's score of -0.01 indicating that Erasca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Scholar Rock 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryErasca beats Scholar Rock on 8 of the 15 factors compared between the two stocks. Get Erasca News Delivered to You Automatically Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ERAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERAS vs. The Competition Export to ExcelMetricErascaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$626.91M$3.44B$6.23B$10.68BDividend YieldN/A2.26%5.71%4.82%P/E Ratio-5.2923.9230.0629.84Price / SalesN/A487.63587.23131.17Price / CashN/A45.5737.0161.44Price / Book1.5910.4012.046.60Net Income-$161.65M-$52.62M$3.32B$276.82M7 Day Performance-1.65%2.08%1.79%2.07%1 Month Performance24.61%10.84%6.28%2.62%1 Year Performance-7.75%13.57%61.13%32.86% Erasca Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERASErasca2.9325 of 5 stars$2.38+7.7%$3.75+57.6%-14.3%$626.91MN/A-5.29120SRRKScholar Rock4.4391 of 5 stars$27.92-0.1%$48.50+73.7%+2.5%$2.69B$33.19M-9.59140NTLAIntellia Therapeutics4.1323 of 5 stars$27.98+13.1%$27.95-0.1%+29.8%$2.66B$57.88M-5.97600HCMHUTCHMED2.8005 of 5 stars$15.10-0.3%$20.88+38.2%-29.6%$2.64B$630.20M0.001,811ALVOAlvotech3.4135 of 5 stars$8.59-1.5%$14.00+63.0%-36.8%$2.63B$560.10M37.351,032Analyst DowngradeBEAMBeam Therapeutics3.7425 of 5 stars$30.62+17.9%$45.92+50.0%+29.2%$2.63B$63.52M-6.80510Analyst ForecastHigh Trading VolumeCDTXCidara Therapeutics3.9727 of 5 stars$100.56-0.9%$151.33+50.5%+751.0%$2.57B$1.27M-9.0490News CoverageAnalyst ForecastIDYAIDEAYA Biosciences4.3273 of 5 stars$30.51+4.3%$44.80+46.8%-3.7%$2.56B$7M-8.0580Analyst ForecastAnalyst RevisionRXRXRecursion Pharmaceuticals2.0209 of 5 stars$6.68+14.0%$7.25+8.5%-9.5%$2.54B$58.84M-3.75400Gap UpAPGEApogee Therapeutics3.1718 of 5 stars$56.94+3.2%$94.00+65.1%+4.6%$2.54BN/A-13.7991Analyst ForecastCPRXCatalyst Pharmaceuticals4.8798 of 5 stars$21.01+2.2%$33.20+58.0%-2.9%$2.52B$491.73M12.7380Positive NewsAnalyst Forecast Related Companies and Tools Related Companies Scholar Rock Alternatives Intellia Therapeutics Alternatives HUTCHMED Alternatives Alvotech Alternatives Beam Therapeutics Alternatives Cidara Therapeutics Alternatives IDEAYA Biosciences Alternatives Recursion Pharmaceuticals Alternatives Apogee Therapeutics Alternatives Catalyst Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ERAS) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredTrade this between 9:30 and 10:45 am ESTIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredThe End of Elon Musk…?While headlines point to collapsing sales and fading tax credits, tech analyst Jeff Brown says Tesla is on the...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Erasca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ERAS Stock Alerts